Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Navidea Biopharmaceuticals Inc NAVB

Healthcare Biotechnology
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Company’s business is focused on... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (PINL:NAVB)

Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations

Business Wire January 26, 2024

Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release

Business Wire December 1, 2023

Navidea Biopharmaceuticals, Inc. Announces NYSE American's Decision to Suspend Trading In Its Common Stock

Business Wire October 5, 2023

Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel

Business Wire August 10, 2023

Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities

Business Wire July 31, 2023

Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination

Business Wire July 28, 2023

Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer

Business Wire July 27, 2023

Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down

Business Wire July 13, 2023

Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets

Business Wire June 30, 2023
View More News ››

Opinion & Analysis (PINL:NAVB)

Navidea Shares Jump 60% on Phase 2b Rheumatoid Arthritis Trial Results

Streetwise Reports October 30, 2019
View More Opinion ››

Bullboard Posts (PINL:NAVB)

RE:SGYP Seeking Alpha Article worth a read...

Appologies, wrong StockBoard..But I do have significant exposure to NAVB and have my shares in a vice...
MirrorWorldMan - August 16, 2014

SGYP Seeking Alpha Article worth a read...

'Trouble for Synergy Pharmaceuticals Shorts with Pending SP-333 Trial Results" August  15 7:24 PM
MirrorWorldMan - August 16, 2014

catalysts?

Anyone know of any potential catalysts upcoming for NAVB? Anything this year to speak of?
jarat - August 15, 2014

Pdufa

Pdufa date in June.  Looking for it to drop on earnings this week.  Will be above 3 by late April
normtrader - March 2, 2014
View more Bullboard ››

Fineqia International Inc.

Fineqia International Inc.

Fineqia is a digital asset business that builds and targets investments in early and growth-stage technology companies that ...
View More »